186551-69-9

Basic information

• Product Name: 3-BROMOMETHYL-PYRAZOLE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 3-BROMOMETHYL-PYRAZOLE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;tert-Butyl 3-(bromomethyl)-1H-pyrazole-1-carboxylate;1H-Pyrazole-1-carboxylic acid, 3-(bromomethyl)-, 1,1-dimethylethyl ester
• CAS NO: 186551-69-9
• Molecular Formula: C₉H₁₃BrN₂O₂
• Molecular Weight: 261.12
• Mol File: 186551-69-9.mol

Chemical Properties

• Boiling Point: 315.3±34.0 °C(Predicted)
• Appearance: /
• Density: 1.42±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -2.08±0.12(Predicted)
• CAS DataBase Reference: 3-BROMOMETHYL-PYRAZOLE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMOMETHYL-PYRAZOLE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(186551-69-9)
• EPA Substance Registry System: 3-BROMOMETHYL-PYRAZOLE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(186551-69-9)

Safety Data

• Hazardous Substances Data: 186551-69-9(Hazardous Substances Data)

Upstream product

• 186551-70-2 tert-butyl 3-methyl-1H-pyrazole-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 186551-71-3 7-methoxynaphthalene-2-sulfonic acid [1-(3-cyanobenzyl)-2-oxopyrrolidin-3-(S)-yl](N-tert-butyloxycarbonylpyrazol-3-ylmethyl)amide 
• 941572-55-0 phenylmethyl (2S)-4-[(1-{[(1,1-dimethylethyl)oxy]carbonyl}-1H-pyrazol-3-yl)methyl]-2-methyl-1-piperazinecarboxylate 

Relevant articles and documents

COMPOUNDS AS GLP-1R AGONISTS

The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or stereoisomers, tautomers, or pharmaceutically acceptable salts of any of the foregoing. Also provided are pharmaceutical compositions containing such compounds, or stereoisomers, tautomers, or pharmaceutically acceptable salts of any of the foregoing. Methods of prepare these compounds and compositions and method of using them to treat or present a disease or a condition mediated by GLP-1R.

PHENOXYMETHYL DERIVATIVES

The invention provides novel compounds having the general formula (I), wherein RA, RB, RC, RC1 and W are as defined herein, compositions including the compounds and methods of using the compounds.

INHIBITORS OF HIF PROLYL HYDROXYLASE

The present invention concerns compounds of formula I or pharmaceutically acceptable salts thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.

NOVEL ANTIVIRAL PYRROLOPYRIDINE DERIVATIVES AND METHOD FOR PREPARING THE SAME

The present invention relates to a pyrrolopyridine derivative represented by the Chemical Formula I, and a racemate or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and relates to an antiviral composition including the same as an active ingredient. The compound of the Chemical Formula I has excellent antiviral activity and selectivity for wild type and resistant HIV-1, and thereby is useful as a therapeutic agent for acquired immune deficiency syndrome (AIDS).

NOVEL ANTIVIRAL PYRROLOPYRIDINE DERIVATIVE AND A PRODUCTION METHOD FOR SAME

The present invention relates to a pyrrolopyridine derivative represented by the Chemical Formula I, and a racemate or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and relates to an antiviral composition including the same as an active ingredient. The compound of the Chemical Formula I has excellent antiviral activity and selectivity for wild type and resistant HIV-1, and thereby is useful as a therapeutic agent for acquired immune deficiency syndrome (AIDS).

BIARYL COMPOUNDS USEFUL AS AGONISTS OF THE GPR38 RECEPTOR

The present invention relates to novel biaryl derivatives such as compounds of formula (I), which have activity as agonists of the GPR38 receptor and the use of such compounds or pharmaceutical compositions thereof in the treatment of gastrointestinal dis

ACE-2 modulating compounds and methods of use thereof

ACE-2 modulating compounds for the treatment of body weight disorders are disclosed. Methods of using the compounds and pharmaceutical compositions containing the compounds are also claimed.

Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa

The discovery of a series of non-peptide factor Xa (FXa) inhibitors incorporating 3-(s)-amino-2-pyrrolidinone as a central template is described. After identifying compound 4, improvements in in vitro potency involved modifications of the liphophilic group and optimizing the angle of presentation of the amidine group to the S1 pocket of FXa. These studies ultimately led to compound RPR120844, a potent inhibitor of FXa (K1 = 7 nM) which shows selectivity for FXa over trypsin, thrombin, and several fibrinolytic serine proteinases. RPR120844 is an effective anticoagulant in both the rat model of FeCl2-induced carotid artery thrombosis and the rabbit model of jugular vein thrombus formation.